![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Information]](https://mdc-test.eprints-hosting.org/style/images/fileicons/other.png) |
Other (Supplementary Information)
1MB |
| Item Type: | Article |
|---|---|
| Title: | Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY |
| Creators Name: | Mansouri, L., Thorvaldsdottir, B., Sutton, L.A., Karakatsoulis, G., Meggendorfer, M., Parker, H., Nadeu, F., Brieghel, C., Laidou, S., Moia, R., Rossi, D., Catherwood, M., Kotaskova, J., Delgado, J., Rodríguez-Vicente, A.E., Benito, R., Rigolin, G.M., Bonfiglio, S., Scarfo, L., Mattsson, M., Davis, Z., Gogia, A., Rani, L., Baliakas, P., Foroughi-Asl, H., Jylhä, C., Skaftason, A., Rapado, I., Miras, F., Martinez-Lopez, J., de la Serna, J., Rivas, J.M.H., Thornton, P., Larráyoz, M.J., Calasanz, M.J., Fésüs, V., Mátrai, Z., Bödör, C., Smedby, K.E., Espinet, B., Puiggros, A., Gupta, R., Bullinger, L., Bosch, F., Tazón-Vega, B., Baran-Marszak, F., Oscier, D., Nguyen-Khac, F., Zenz, T., Terol, M.J., Cuneo, A., Hernández-Sánchez, M., Pospisilova, S., Mills, K., Gaidano, G., Niemann, C.U., Campo, E., Strefford, J.C., Ghia, P., Stamatopoulos, K. and Rosenquist, R. |
| Abstract: | Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3-9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53, BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management. |
| Keywords: | Cancer Genetics, Genetics Research |
| Source: | Leukemia |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Volume: | 37 |
| Number: | 2 |
| Page Range: | 339-347 |
| Date: | February 2023 |
| Additional Information: | Erratum in: Leukemia 37(2):504. |
| Official Publication: | https://doi.org/10.1038/s41375-022-01802-y |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
